BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 15840971)

  • 1. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
    Vaupel P; Dunst J; Engert A; Fandrey J; Feyer P; Freund M; Jelkmann W
    Onkologie; 2005 Apr; 28(4):216-21. PubMed ID: 15840971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
    Crawford J
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
    Durmaz O; Demirkaya M; Sevinir B
    Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rHuEPO and improved treatment outcomes: potential modes of action.
    Blackwell K; Gascón P; Sigounas G; Jolliffe L
    Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
    Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
    Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy.
    Massa E; Madeddu C; Lusso MR; Gramignano G; Mantovani G
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):175-82. PubMed ID: 16213740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing?
    Dunst J
    Strahlenther Onkol; 2004 Nov; 180(11):671-81. PubMed ID: 15549184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
    Henry DH
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial experience using erythropoietin during radiation therapy.
    Lavey RS
    Strahlenther Onkol; 1998 Dec; 174 Suppl 4():24-30. PubMed ID: 9879344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of iron in optimizing responses of anemic cancer patients to erythropoietin.
    Glaspy J; Cavill I
    Oncology (Williston Park); 1999 Apr; 13(4):461-73; discussion 477-8, 483-8. PubMed ID: 10234700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. rHuEPO and treatment outcomes: the preclinical experience.
    Ludwig H
    Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
    Beutel G; Ganser A
    Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment.
    Adamson JW; Spivak JL
    Surgery; 1994 Jan; 115(1):7-15. PubMed ID: 8284765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The blue cross blue shield assessment technology review: summary of findings.
    Bennett CL
    Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
    Anand A; Anand A; Anand N
    Cancer; 1996 May; 77(9):1960-1. PubMed ID: 8646701
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer-related anemia and recombinant human erythropoietin--an updated overview.
    Bohlius J; Weingart O; Trelle S; Engert A
    Nat Clin Pract Oncol; 2006 Mar; 3(3):152-64. PubMed ID: 16520805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erythropoietin: a study of its use in oncohematology].
    Fernández Martín JM; Villa Rubio A; Cameán Fernández M; Borrero Rubio JM; Martínez Díaz C; Díaz Navarro J; Moreno Sánchez FC; Serrano Ruiz FJ
    Farm Hosp; 2004; 28(1):20-8. PubMed ID: 15012175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?
    Harrison L; Blackwell K
    Oncologist; 2004; 9 Suppl 5():31-40. PubMed ID: 15591420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.